SUVmax Predicts Disease Progression after Stereotactic Ablative Radiotherapy in Stage I Non-small Cell Lung Cancer.

Cancer Res Treat · 2020 · PMC6962475 · PMID 31122008

Europe PMC DOI

hedged sentences

0.0590

closest p · 1.2× alpha

0.0590

boldest claim

The sentences

borderline significancep=0.059so close (0.05 < p ≤ 0.1)

High pretreatment SUVmax showed decreased regional progression-free survival with borderline significance (p=0.059) but was not significant in relation to local control and distant progression-free survival.

also in 7,017 other papers

marginal significancep=0.059so close (0.05 < p ≤ 0.1)

In multivariate analyses pre-SABR SUVmax remained statistically significant in correlation to OS (p=0.024; hazard ratio [HR], 3.2; 95% confidence interval [CI], 1.2 to 8.8) and with marginal significance in regards to regional progression-free survival (p=0.059; HR, 32.5; 95% CI, 2.6 to 402.5).

also in 5,069 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.